RENE will place 181.3M shares in 3 separate tranches at a price of 5.5 pence, a 17% discount to the closing price on 12/10/10 of 6.6 pence raising £10M from investors. Read more…
LSE: RENE.L confirmed that the first patient has been treated to evaluate neural stem cell therapy in stroke patients. Read more…
New data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. The results of these studies showed that the CTX cells express several trophic and pro-angiogenic factors in culture and also induce endothelial cell markers Read more…
RENE.L’s loss widened to FY10 (3/31/10) £5.85 M from £ 3.67 M in the prior year. On a per share basis, net loss was 1.8 pence, compared to a loss of 2.4 pence in the previous year. Loss before income taxes widened to £6.22 M, from £4.67M in the previous year. Revenues were GBP 31K, down from £ 93K in the prior year. Read more…
Positive data from a number of new pre-clinical studies using its CTX stem cell line for stroke was announced (4/29/10). The new data include the results from a recent pre-clinical efficacy study using ReNeuron’s CTX stem cell line, which RENE is taking forward into the clinic as a (ReN001) therapy for disabled stroke patients. This finding supports the mode of administration to be used in RENE’s UK Phase I clinical trial with ReN001 in disabled stroke patients with direct injection of the cells close to the area of stroke brain damage.
ReNeuron Group (RENE.L) announced the placing of 94.4 M new ordinary shares with existing and new institutional and qualifying individual shareholders on 2/22/10. This placement was comprised 2 closings and will trade on AIM.
RENE.LON announced that it has raised (GBP) £4.7 M (before expenses), from existing and new institutional shareholders issuing/selling 94,400,000 new shares. The 1st closing for 16,800,000 is expected on 3/18/10 and the 2nd closing for 77,600,000 is expected on 3/19/10. The net proceeds will provide RQE.L to satisfy its burn rate for at least the next 12 months. The net proceeds will further the Phase I trial ReN001, a stem cell therapy for disabled stroke patients, pre-clinical testing of ReN009 therapy for peripheral arterial disease and optimization/scale-up of the 2nd generation CTX stem cell line as well as providing for general working capital purposes.
ReNeuron (LON: RENE) has been … finally … given full regulatory approval by the UK Gene Therapy Advisory Committee to initiate a stem cell trial for ischemic stroke after a 5 years approval cycle.
RENE.L also has new preclinical data backing the efficacy of its lead CTX stem cell line for peripheral arterial disease. Read more…
ReNeuron is a UK-based stem cell company. Their primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. RENE.L’s shares are traded on the London AIM market.
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.